AU2014332458B2 - Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies - Google Patents

Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies Download PDF

Info

Publication number
AU2014332458B2
AU2014332458B2 AU2014332458A AU2014332458A AU2014332458B2 AU 2014332458 B2 AU2014332458 B2 AU 2014332458B2 AU 2014332458 A AU2014332458 A AU 2014332458A AU 2014332458 A AU2014332458 A AU 2014332458A AU 2014332458 B2 AU2014332458 B2 AU 2014332458B2
Authority
AU
Australia
Prior art keywords
binding
igm
heavy chain
amino acid
bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014332458A
Other languages
English (en)
Other versions
AU2014332458A1 (en
Inventor
Bruce Keyt
Leonard George Presta
Rency YOSHIMURA
Fen Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IGM Biosciences Inc
Original Assignee
IGM Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IGM Biosciences Inc filed Critical IGM Biosciences Inc
Publication of AU2014332458A1 publication Critical patent/AU2014332458A1/en
Assigned to IGM BIOSCIENCES A/S reassignment IGM BIOSCIENCES A/S Request for Assignment Assignors: IGM BIOSCIENCES, INC.
Assigned to IGM BIOSCIENCES, INC. reassignment IGM BIOSCIENCES, INC. Request for Assignment Assignors: IGM BIOSCIENCES A/S
Application granted granted Critical
Publication of AU2014332458B2 publication Critical patent/AU2014332458B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2014332458A 2013-09-05 2014-09-04 Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies Ceased AU2014332458B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361874277P 2013-09-05 2013-09-05
US201361874284P 2013-09-05 2013-09-05
US61/874,284 2013-09-05
US61/874,277 2013-09-05
PCT/US2014/054079 WO2015053887A1 (en) 2013-09-05 2014-09-04 Constant chain modified bispecific, penta- and hexavalent ig-m antibodies

Publications (2)

Publication Number Publication Date
AU2014332458A1 AU2014332458A1 (en) 2016-04-07
AU2014332458B2 true AU2014332458B2 (en) 2020-03-12

Family

ID=51542496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014332458A Ceased AU2014332458B2 (en) 2013-09-05 2014-09-04 Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies

Country Status (9)

Country Link
US (1) US10351631B2 (OSRAM)
EP (1) EP3041862B1 (OSRAM)
JP (1) JP6721505B2 (OSRAM)
KR (1) KR102306492B1 (OSRAM)
CN (1) CN105722855B (OSRAM)
AU (1) AU2014332458B2 (OSRAM)
CA (1) CA2922830A1 (OSRAM)
DK (1) DK3041862T3 (OSRAM)
WO (1) WO2015053887A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
BR112013019975A2 (pt) 2011-02-28 2017-08-01 Hoffmann La Roche proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
RU2016115866A (ru) * 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
BR112016018313A8 (pt) 2014-02-10 2018-06-12 Igm Biosciences Inc Moléculas de ligação multiespecíficas iga
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
KR102435324B1 (ko) 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
SI3265575T1 (sl) * 2015-03-04 2021-08-31 Igm Biosciences, Inc. Vezne molekule CD20 in njihove uporabe
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
ES2996834T3 (en) * 2015-09-30 2025-02-13 Igm Biosciences Inc Binding molecules with modified j-chain
EP3356401B1 (en) * 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
CA3021669A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
WO2018187702A2 (en) 2017-04-07 2018-10-11 Igm Biosciences A/S Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
BR112020017296A2 (pt) 2018-03-01 2020-12-29 Igm Biosciences, Inc. Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
CN114269785A (zh) 2019-08-15 2022-04-01 Igm生物科学股份有限公司 免疫刺激性多聚体结合分子
CN115485299A (zh) 2020-04-22 2022-12-16 Igm生物科学股份有限公司 Pd-1激动剂多聚结合分子
CA3245061A1 (en) 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T-CELL RECEIVER MULTIMERS AND THEIR USES
WO2024073482A1 (en) * 2022-09-28 2024-04-04 Dren Bio, Inc. Multispecific antibodies and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008548A2 (en) * 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
US20130089547A1 (en) * 2011-09-26 2013-04-11 Jn Biosciences Llc Hybrid Constant Regions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
AU2004240782B2 (en) 2003-05-23 2011-04-21 Crucell Holland B.V. Production of recombinant IGM in per.C6 cells
DK1814913T3 (en) 2004-11-05 2015-09-28 Univ Leland Stanford Junior ANTIBODY-INDUCED CELL membrane damage.
US8349332B2 (en) * 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
WO2009089004A1 (en) * 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
AU2013200903B2 (en) 2012-02-08 2015-05-14 Mcure Biosciences Inc. CDIM binding proteins and uses thereof
SG10201806025TA (en) 2014-01-16 2018-08-30 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
BR112016018313A8 (pt) 2014-02-10 2018-06-12 Igm Biosciences Inc Moléculas de ligação multiespecíficas iga
CN112759650B (zh) 2014-04-03 2024-10-01 Igm生物科学股份有限公司 修饰的j链
KR102435324B1 (ko) 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
SI3265575T1 (sl) 2015-03-04 2021-08-31 Igm Biosciences, Inc. Vezne molekule CD20 in njihove uporabe
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
AU2016249404B2 (en) 2015-04-17 2021-01-21 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
ES2996834T3 (en) 2015-09-30 2025-02-13 Igm Biosciences Inc Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
CA3021669A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
US20190338040A1 (en) 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
US20190338041A1 (en) 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
AU2017300647A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric GITR binding molecules and uses thereof
EP3487533A4 (en) 2016-07-20 2020-03-25 IGM Biosciences, Inc. MULTIMERE OX40-BINDING MOLECULES AND USES THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008548A2 (en) * 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
US20130089547A1 (en) * 2011-09-26 2013-04-11 Jn Biosciences Llc Hybrid Constant Regions

Also Published As

Publication number Publication date
CN105722855B (zh) 2021-04-23
KR20160077036A (ko) 2016-07-01
DK3041862T3 (da) 2020-07-27
EP3041862A1 (en) 2016-07-13
CA2922830A1 (en) 2015-04-16
US10351631B2 (en) 2019-07-16
US20160222132A1 (en) 2016-08-04
CN105722855A (zh) 2016-06-29
KR102306492B1 (ko) 2021-09-29
WO2015053887A1 (en) 2015-04-16
BR112016004768A8 (pt) 2018-06-12
JP6721505B2 (ja) 2020-07-15
JP2016531924A (ja) 2016-10-13
EP3041862B1 (en) 2020-05-06
BR112016004768A2 (OSRAM) 2017-09-05
AU2014332458A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
AU2014332458B2 (en) Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
US12344679B2 (en) CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
JP7314356B2 (ja) 改変ｊ鎖を有する結合分子
CN111683970A (zh) C-kit结合剂
CN116897166A (zh) 抗GPRC5DxBCMAxCD3三特异性抗体及其用途
CN106397598B (zh) 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
CN105408356A (zh) 双特异性构建体及其用于治疗多种疾病的用途
CA2939191A1 (en) Iga multi-specific binding molecules
US20250230240A1 (en) Variant antibodies that bind gamma-delta t cell receptors
WO2021160138A1 (zh) 抗表皮生长因子受体的抗原结合蛋白及其应用
WO2024046234A1 (zh) 抗人补体c5抗体以及其融合蛋白
CN115558024A (zh) 抗b7-h3单克隆抗体及其用途
CN121057752A (zh) 铰链经修饰的双特异性抗体
CA3245807A1 (en) Antigen-binding molecule specifically binding to GPRC5D and CD3 and its medical use
CN115160440B (zh) 新型双特异性抗体
BR112016004768B1 (pt) Moléculas de ligação com uma estrutura em anel pentamérica ou hexamérica
JP2025528101A (ja) 多重特異性ポリペプチド複合体
WO2024099320A1 (zh) 补体抑制杂合蛋白突变体及其抗体融合蛋白
WO2024074145A1 (zh) 一种结合baffr和cd3的双特异性抗体及其应用
WO2025131081A1 (zh) 抗tnfr2抗体及其用途
CN118667026A (zh) 抗muc17*cd3*cd28三特异性抗体
CN115073596A (zh) 一种人源化Claudin 18.2抗体及其应用

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: IGM BIOSCIENCES A/S

Free format text: FORMER APPLICANT(S): IGM BIOSCIENCES, INC.

PC1 Assignment before grant (sect. 113)

Owner name: IGM BIOSCIENCES, INC.

Free format text: FORMER APPLICANT(S): IGM BIOSCIENCES A/S

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired